Were Cytodyn's earlier (April/May) eIND dosages, also controlled and limited by what the FDA said we could do, or maybe controlled by what we indicated the doses needed to be, and then dosage became "set"?

Cytodyn could have designed the trial with several different arms of the study, each arm with different dosages, but then, each arm would require too many volunteers to provide adequate "power" for the p value calculation. And the data would have been excessive and complicated, but, do-able.